Controversial genetics testing startup Nucleus Genomics raises $14M Series A
The company, founded by 25-year-old Kian Sadeghi, announced a $14 million Series A, bringing its total funding to about $32 million.
Myriad Genetics price target lowered to $14 from $24 at Piper Sandler
Piper Sandler analyst David Westenberg lowered the firm’s price target on Myriad Genetics (MYGN) to $14 from $24 and keeps a Neutral rating on ...
alleywatch.com9h
Nucleus Raises $14M to Transform Genetic Health Testing
AlleyWatch sat down with Nucleus CEO and Founder Kian Sadeghi to learn more about the business, its future plans, and recent ...
TCTMD5h
Genomadix Inc. Announces Health Canada License for Rapid Genetic Test to Aid Therapy Selection for Stroke and Cardiovascular Disease Patients
The Cube CYP2C19 test can be used to aid clinicians in determining therapeutic strategy for drugs metabolized by the CYP450 2C19 genetic pathway. Genomadix CubeTM CYP2C19 System identifies the CYP2C19 ...
labiotech14h
Seven genomics startups to look out for
Discover the top genomics startups revolutionizing genome sequencing technologies to enhance disease prevention and treatment ...